Related Experiment Video

Updated: Jul 8, 2026

A Simple and Efficient Approach to Construct Mutant Vaccinia Virus Vectors
09:16

A Simple and Efficient Approach to Construct Mutant Vaccinia Virus Vectors

Published on: October 30, 2016

Preclinical and clinical studies of recombinant poxvirus vaccines for carcinoma therapy

Philip M Arlen1, James L Gulley, Ravi A Madan

  • 1Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-1750, USA. arlenp@mail.nih.gov

Critical Reviews in Immunology
|January 17, 2008
PubMed

Insights

Novel poxvirus vaccines targeting tumor-associated antigens (TAAs) enhanced T-cell responses and survival in clinical trials. Combination therapies showed promise in prolonging disease progression time.

Area of Science:

  • Immunology
  • Oncology
  • Vaccinology

Background:

  • Tumor-associated antigens (TAAs) are poorly immunogenic, limiting natural anti-tumor immune responses.
  • Vaccine strategies aim to enhance T-cell activation against TAAs beyond natural host capabilities.

Purpose of the Study:

  • To evaluate poxvirus vectors expressing TAAs and costimulatory molecules (TRICOM) for their ability to induce antigen-specific T-cell responses.
  • To assess the clinical efficacy of TRICOM vaccines in cancer patients, including combinations with other therapies.

Main Methods:

  • Preclinical studies utilized recombinant poxvirus vectors encoding TAAs and costimulatory molecules (B7-1, ICAM-1, LFA-3) designated TRICOM.
  • Clinical trials involved TRICOM vaccines expressing TAAs (PSA, CEA, MUC-1) and assessed combinations with radiation, chemotherapy, and hormone therapy.

Main Results:

  • Preclinical studies showed greatest antigen-specific T-cell responses and correlated survival with CEA-TRICOM vaccines.
  • Clinical trials demonstrated preliminary evidence of prolonged time to disease progression and antigen cascade postvaccination when TRICOM vaccines were combined with other cancer treatments.

Conclusions:

  • Poxvirus-based TRICOM vaccines effectively induce antigen-specific T-cell responses against TAAs.
  • Combination strategies involving TRICOM vaccines show potential for improving clinical outcomes in cancer patients.

More Related Videos

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Rapid, Seamless Generation of Recombinant Poxviruses using Host Range and Visual Selection09:25

Rapid, Seamless Generation of Recombinant Poxviruses using Host Range and Visual Selection

Published on: May 24, 2020

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Smallpox01:24

Smallpox

Smallpox is a severe contagious disease caused by the Variola major virus, a double-stranded DNA member of the Poxviridae family.Variola major transmission occurs primarily via inhalation of virus-laden droplets or direct contact with infectious scabs. The incubation period averages approximately seven days, although it may range from 7 to 17 days depending on the inoculum and host factors.Clinically, the prodromal phase is marked by an abrupt onset of high fever, malaise, headache, and myalgia.
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...